Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
What Is the New 'New Normal' of Chinese Pharma Going To Be?
Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on multiple new moves of the Chinese government to deepen he... (7/12/2019)
   
Cross-sector Synergy: China Innovation at Merck (7/19/2019)
U.S. Targeting of Chinese Scientists Fuels a Brain Drain (7/18/2019)
Trade War and China's Changing Trade Mark Law (7/16/2019)
What Is the New 'New Normal' of Chinese Pharma Going To Be? (7/12/2019)
2019 Rubio's Huawei Proposal Should Worry US Tech, Pharma Companies (7/9/2019)
UCSD Doctor Resigns After inewsource Raised Questions About His China Business Ties (7/9/2019)
US-China Trade War Gets Mixed Reviews from Chinese Attendees at BIO (6/28/2019)
Who Will Win the PD-1 War in China? (6/27/2019)
The Hidden Challenges of China's Booming Medical AI Market (6/25/2019)
Chinese Pharma and Biotech Companies Tap U.S. Talent (6/20/2019)
Bribes and Backdoor Deals Help Foreign Firms Sell to China’s Hospitals (6/18/2019)
Patient-Centric Trials in China: An Opportunity to Innovate (6/18/2019)
WSJ: China Biotechs Lure Industry Talents in the U.S. (6/17/2019)
AstraZeneca Markets an Herbal-Based Remedy to Expand in China (6/13/2019)
The U.S. Is Purging Chinese Cancer Researchers From Top Institutions (6/13/2019)
Recent Executive Moves  (7/19/2019)
NHSA Publishes 2018 National Basic Medic...  (7/19/2019)
Chinese Pharma Cos Gains 47 Additional A...  (7/19/2019)
Snapshot of Leading Chinese Drug Brands ...  (7/19/2019)
Novartis Wins Chinese Approval of MS Dru...  (7/19/2019)
CDE Seeks Feedbacks on Implementation Su...  (7/19/2019)
China Begins Phase II Trial of Long-last...  (7/19/2019)
Celltrion and Nan Fung Group to Establis...  (7/19/2019)
Alphamab Oncology Files IPO at HKEX  (7/18/2019)
GenScript's Biologics R&D and Produc...  (7/18/2019) (free)
State Council Issues Policy to Establish...  (7/18/2019) (free)
Snapshot of BMI System Financial Perform...  (7/18/2019)
SMEI Releases Rankings of Top 100 Chines...  (7/18/2019)
CDE Unleashes Mid-Year Report on Clinica...  (7/18/2019)
60% of 135 Listed Biopharma Companies Is...  (7/17/2019)
PhRMA Calls for Trade Deals That Force Countries to Pay ...
IQVIA: Global Pharma to Grow Slower in the Next Five Yea...
Pfizer and GSK Announce JV to Create a Global Consumer H...
Top 25 Global Pharmaceutical Companies by Market Cap 201...
CANbridge Receives IND Approval to Commence CAN008 Phase...
Snapshot of Leading Chinese Drug Brands by Retail Sales in 2018...
SMEI President Reviews Pharma Industry Performance with Lowered...
IQVIA: Chinese Hospital Drug Market Up 4.3% in MAT Q1/2019
Review of Chemical Drug Sales at Chinese Public Medical Institu...
India Calls for Clear Roadmap from China to Ramp Up Indian Phar...
Chinese Pharma Cos Gains 47 Additional ANDAs in the U.S.
Novartis Wins Chinese Approval of MS Drug Gilenya
Celltrion and Nan Fung Group to Establish JV for Biosimilars...
Alphamab Oncology Files IPO at HKEX
GenScript's Biologics R&D and Production Center Becomes ...
CDE Seeks Feedbacks on Implementation Suggestions for Tr...
State Council Issues Policy to Establish Inspection Forc...
CDE Unleashes Mid-Year Report on Clinical Trial Registra...
NMPA Issues New Document on Linked Evaluation and Approv...
CDE Issues Notice on Reference of Exemption Guidelines f...
U.S. Seeks Extradition of Chinese Scientist in GSK Trade Sec...
CNIPA Issues 2019 Work Guidance on Promoting the High-Qualit...
China Adopts Vaccine Management Law with Effect from Dec. 1,...
China to Raise Punishments for Shoddy Vaccines in 3rd Review...
US Senators Questions HHS Money and Chinese Genomics Firms
China Accounted for 67% of India's Bulk Drug Imports in ...
Athenex Voluntarily Suspends Production at Its Chongqing...
China Issues Draft Positive List of Antibacterial Active...
Chinese API Industry's Environmental Shake-up Disrupts V...
U.S. Senators Propose Bill to Sanction Chinese Pharmchem...
China Begins Phase II Trial of Long-lasting HIV Vaccine
Takeda Files NDA for Entyvio (Vedolizumab) in China
Novartis Files NDA for Second Indication of Dabrafenib/T...
Priority Review Granted to BeiGene’s Supplemental NDA i...
Syncore Set to Initiate Phase III Trial of Cancer Drug
NHSA Publishes 2018 National Basic Medical Insurance Sec...
Snapshot of BMI System Financial Performance in H1/2019
China Daily: Latest Healthy China Guideline Targets Chro...
State Council Issues the Action Plan for Healthy China I...
Central Government Urges to Enhanced Basic Medical Care ...
Recent Executive Moves
Swiss Agrees to Extradite Chinese Scientist to US for Corp...
Recent Executive Moves
Recent Executive Moves
Recent Executive Moves
Upcoming Event: Measuring Business Impact & ROI
Upcoming Event: Situational Training Needs Analysis
China Launches Nasdaq-style Tech Board in Shanghai, Expe...
Upcoming Event: Microbiome Movement – Drug Development ...
Upcoming Event: Asia-Pacific Pharma IP Leader Summit 201...
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON to Hold Pharma China Ann...
  WiCON Publishes the China Phar...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links